Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Kim M, Gwak J, Hwang S, Yang S, Jeong SM
In proof-of-concept studies, NNMT inhibitors (NNMTis) have demonstrated promise as potential treatments for obesity and obesity-related metabolic comorbidities (e.g., T2D, fatty liver) 8,9,13
however, if SGLT2is are not tolerated or are contraindicated, or if eGFR is less than adequate, a GLP-1RA with proven CV benefit can be added ( In recent guidelines on diabetes, prediabetes, and CVD from the European Society of Cardiology, in collaboration with the EASD, GLP-1RAs with proven CV benefit (liraglutide, semaglutide, and dulaglutide) are recommended as an add-on therapy to metformin ( Mechanisms for the Cardiovascular Benefits of GLP-1RAS Different mechanisms have been proposed to explain the CV benefits elicited by some GLP-1RAs ( 1c , body weight, and systolic blood pressure were also those associated with CV-event reduction
In 2026 zullen er ook weer nieuwe Kennistafels worden belegd
The more objective data you bring, the better the clinical decisions will be
Related Reading GLP-1 Oral Medications Glp-1 Vs Semaglutide Oral Wegovy Vs Injection Wegovy Pill Vs Injection Orforglipron Phase 3 How Long Have GLP-1 Drugs Actually Been Around
